Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ajanta Pharma has informed that it enclosed the schedule of Analyst/Institutional Investor Meetings with the Company. The company has confirmed that the discussion during these meetings will be strictly on the basis of already published information and no Unpublished Price Sensitive Information is proposed to be discussed in these meetings.
The above information is a part of company’s filings submitted to BSE.
